{"id":246972,"date":"2026-11-09T22:13:24","date_gmt":"2026-11-10T04:13:24","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2026\/11\/glp-1-drugs-getting-new-labels-warning-of-rare-vision-loss-condition"},"modified":"2026-11-09T22:13:24","modified_gmt":"2026-11-10T04:13:24","slug":"glp-1-drugs-getting-new-labels-warning-of-rare-vision-loss-condition","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2026\/11\/glp-1-drugs-getting-new-labels-warning-of-rare-vision-loss-condition","title":{"rendered":"GLP-1 drugs getting new labels warning of rare vision-loss condition"},"content":{"rendered":"\n<p>All GLP-1 drugs, which include popular brands like Ozempic and Wegovy, will soon carry new labels warning people taking the medications about a possible side effect that could lead to permanent vision loss.<\/p>\n<p>Why you should care:<\/p>\n<p>The Food and Drug Administration explained the labels will alert patients to a potential eye condition known as non-arteritic anterior ischemic optic neuropathy. While doctors do not know what causes the rare condition, it can lead to decreased blood flow through the optic nerve.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>All GLP-1 drugs, which include popular brands like Ozempic and Wegovy, will soon carry new labels warning people taking the medications about a possible side effect that could lead to permanent vision loss. Why you should care: The Food and Drug Administration explained the labels will alert patients to a potential eye condition known as [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-246972","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/246972","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=246972"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/246972\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=246972"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=246972"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=246972"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}